Compounds for the treatment of braf-associated diseases and disorders

Provided herein are compounds of the Formula I:and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant an...

Full description

Saved in:
Bibliographic Details
Main Authors BARBOUR, PATRICK MICHAEL, TARLTON, EUGENE, BROWN, KATIE KEATON, KAHN, DEAN RUSSELL, PRIGARO, BRETT JOSEPH, REN, LI, HICKEN, ERIK JAMES, MORENO, DAVID AUSTIN, NEWHOUSE, BRADLEY JON, METCALF, ANDREW TERRANCE, PAJK, SPENCER PHILLIP, LAIRD, ELLEN RUTH, COOK, ADAM WADE
Format Patent
LanguageChinese
English
Published 01.10.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are compounds of the Formula I:and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
Bibliography:Application Number: TW20209121279